This study suggests that obesity is associated with an increased risk of recurrence among patients with hormone receptor–positive breast cancer treated with aromatase inhibitors, highlighting the need for optimization of care in patients with breast cancer and obesity. The gene discussed is NR4A1; the disease is obesity due to melanocortin 4 receptor deficiency.